362 related articles for article (PubMed ID: 32620763)
1. Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation.
Barbier-Torres L; Fortner KA; Iruzubieta P; Delgado TC; Giddings E; Chen Y; Champagne D; Fernández-Ramos D; Mestre D; Gomez-Santos B; Varela-Rey M; de Juan VG; Fernández-Tussy P; Zubiete-Franco I; García-Monzón C; González-Rodríguez Á; Oza D; Valença-Pereira F; Fang Q; Crespo J; Aspichueta P; Tremblay F; Christensen BC; Anguita J; Martínez-Chantar ML; Rincón M
Nat Commun; 2020 Jul; 11(1):3360. PubMed ID: 32620763
[TBL] [Abstract][Full Text] [Related]
2. The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury.
Barbier-Torres L; Iruzubieta P; Fernández-Ramos D; Delgado TC; Taibo D; Guitiérrez-de-Juan V; Varela-Rey M; Azkargorta M; Navasa N; Fernández-Tussy P; Zubiete-Franco I; Simon J; Lopitz-Otsoa F; Lachiondo-Ortega S; Crespo J; Masson S; McCain MV; Villa E; Reeves H; Elortza F; Lucena MI; Hernández-Alvarez MI; Zorzano A; Andrade RJ; Lu SC; Mato JM; Anguita J; Rincón M; Martínez-Chantar ML
Nat Commun; 2017 Dec; 8(1):2068. PubMed ID: 29233977
[TBL] [Abstract][Full Text] [Related]
3. MCJ/DnaJC15, an endogenous mitochondrial repressor of the respiratory chain that controls metabolic alterations.
Hatle KM; Gummadidala P; Navasa N; Bernardo E; Dodge J; Silverstrim B; Fortner K; Burg E; Suratt BT; Hammer J; Radermacher M; Taatjes DJ; Thornton T; Anguita J; Rincon M
Mol Cell Biol; 2013 Jun; 33(11):2302-14. PubMed ID: 23530063
[TBL] [Abstract][Full Text] [Related]
4. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease.
Fernández-Tussy P; Fernández-Ramos D; Lopitz-Otsoa F; Simón J; Barbier-Torres L; Gomez-Santos B; Nuñez-Garcia M; Azkargorta M; Gutiérrez-de Juan V; Serrano-Macia M; Rodríguez-Agudo R; Iruzubieta P; Anguita J; Castro RE; Champagne D; Rincón M; Elortza F; Arslanow A; Krawczyk M; Lammert F; Kirchmeyer M; Behrmann I; Crespo J; Lu SC; Mato JM; Varela-Rey M; Aspichueta P; Delgado TC; Martínez-Chantar ML
Mol Metab; 2019 Nov; 29():40-54. PubMed ID: 31668391
[TBL] [Abstract][Full Text] [Related]
5. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
[TBL] [Abstract][Full Text] [Related]
6. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease.
Lee J; Park JS; Roh YS
Arch Pharm Res; 2019 Nov; 42(11):935-946. PubMed ID: 31571145
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease.
Xu Y; Zhu Y; Hu S; Pan X; Bawa FC; Wang HH; Wang DQ; Yin L; Zhang Y
Mol Metab; 2021 Sep; 51():101244. PubMed ID: 33930596
[TBL] [Abstract][Full Text] [Related]
8. OXPHOS-Mediated Induction of NAD+ Promotes Complete Oxidation of Fatty Acids and Interdicts Non-Alcoholic Fatty Liver Disease.
Akie TE; Liu L; Nam M; Lei S; Cooper MP
PLoS One; 2015; 10(5):e0125617. PubMed ID: 25933096
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice.
Duan J; Wang Z; Duan R; Yang C; Zhao R; Feng Q; Qin Y; Jiang J; Gu S; Lv K; Zhang L; He B; Birnbaumer L; Yang S; Chen Z; Yang Y
Hepatology; 2022 Jan; 75(1):140-153. PubMed ID: 34510514
[TBL] [Abstract][Full Text] [Related]
10. Ginkgolide A ameliorates non-alcoholic fatty liver diseases on high fat diet mice.
Jeong HS; Kim KH; Lee IS; Park JY; Kim Y; Kim KS; Jang HJ
Biomed Pharmacother; 2017 Apr; 88():625-634. PubMed ID: 28142119
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals.
Goikoetxea-Usandizaga N; Serrano-Maciá M; Delgado TC; Simón J; Fernández Ramos D; Barriales D; Cornide ME; Jiménez M; Pérez-Redondo M; Lachiondo-Ortega S; Rodríguez-Agudo R; Bizkarguenaga M; Zalamea JD; Pasco ST; Caballero-Díaz D; Alfano B; Bravo M; González-Recio I; Mercado-Gómez M; Gil-Pitarch C; Mabe J; Gracia-Sancho J; Abecia L; Lorenzo Ó; Martín-Sanz P; Abrescia NGA; Sabio G; Rincón M; Anguita J; Miñambres E; Martín C; Berenguer M; Fabregat I; Casado M; Peralta C; Varela-Rey M; Martínez-Chantar ML
Hepatology; 2022 Mar; 75(3):550-566. PubMed ID: 34510498
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 72 regulates hepatic lipid accumulation.
Archer AE; Rogers RS; Von Schulze AT; Wheatley JL; Morris EM; McCoin CS; Thyfault JP; Geiger PC
Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R696-R707. PubMed ID: 29924632
[TBL] [Abstract][Full Text] [Related]
13. The PDE5 inhibitor udenafil ameliorates nonalcoholic fatty liver disease by improving mitochondrial function.
Yu HM; Chung HK; Park KS
Biochem Biophys Res Commun; 2021 Jun; 558():57-63. PubMed ID: 33895552
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial dysfunction in high-fat diet-induced nonalcoholic fatty liver disease: The alleviating effect and its mechanism of Polygonatum kingianum.
Yang XX; Wang X; Shi TT; Dong JC; Li FJ; Zeng LX; Yang M; Gu W; Li JP; Yu J
Biomed Pharmacother; 2019 Sep; 117():109083. PubMed ID: 31387169
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression.
Bellanti F; Villani R; Tamborra R; Blonda M; Iannelli G; di Bello G; Facciorusso A; Poli G; Iuliano L; Avolio C; Vendemiale G; Serviddio G
Redox Biol; 2018 May; 15():86-96. PubMed ID: 29220698
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial oxidative function in NAFLD: Friend or foe?
Shum M; Ngo J; Shirihai OS; Liesa M
Mol Metab; 2021 Aug; 50():101134. PubMed ID: 33276146
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
18. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent.
Goikoetxea-Usandizaga N; Bravo M; Egia-Mendikute L; Abecia L; Serrano-Maciá M; Urdinguio RG; Clos-García M; Rodríguez-Agudo R; Araujo-Legido R; López-Bermudo L; Delgado TC; Lachiondo-Ortega S; González-Recio I; Gil-Pitarch C; Peña-Cearra A; Simón J; Benedé-Ubieto R; Ariño S; Herranz JM; Azkargorta M; Salazar-Bermeo J; Martí N; Varela-Rey M; Falcón-Pérez JM; Lorenzo Ó; Nogueiras R; Elortza F; Nevzorova YA; Cubero FJ; Saura D; Martínez-Cruz LA; Sabio G; Palazón A; Sancho-Bru P; Elguezabal N; Fraga MF; Ávila MA; Bataller R; Marín JJG; Martín F; Martínez-Chantar ML
Hepatology; 2023 Sep; 78(3):878-895. PubMed ID: 36745935
[TBL] [Abstract][Full Text] [Related]
19. HCBP6 deficiency exacerbates glucose and lipid metabolism disorders in non-alcoholic fatty liver mice.
Lu H; Yuan X; Zhang Y; Han M; Liu S; Han K; Liang P; Cheng J
Biomed Pharmacother; 2020 Sep; 129():110347. PubMed ID: 32535386
[TBL] [Abstract][Full Text] [Related]
20. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
